Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non–Small-Cell Lung Cancer | Zendy

ChangQi Zhu | Zendy; Keyue Ding | Zendy; Dan Strumpf | Zendy; Barbara A. Weir | Zendy; Matthew Meyerson | Zendy; Nathan A. Pennell | Zendy; Roman K. Thomas | Zendy; Katsuhiko Naoki | Zendy; Christine LaddAcosta | Zendy; Ni Liu | Zendy; Melania Pintilie | Zendy; Sandy Der | Zendy; Lesley Seymour | Zendy; Igor Jurišica | Zendy; Frances A. Shepherd | Zendy; MingSound Tsao | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non–Small-Cell Lung Cancer

Author(s) -

ChangQi Zhu,

Keyue Ding,

Dan Strumpf,

Barbara A. Weir,

Matthew Meyerson,

Nathan A. Pennell,

Roman K. Thomas,

Katsuhiko Naoki,

Christine LaddAcosta,

Ni Liu,

Melania Pintilie,

Sandy Der,

Lesley Seymour,

Igor Jurišica,

Frances A. Shepherd,

MingSound Tsao

Publication year - 2010

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2009.26.4325

Subject(s) - medicine , vinorelbine , oncology , gene signature , hazard ratio , cisplatin , lung cancer , stage (stratigraphy) , microarray , gene expression profiling , chemotherapy , adjuvant chemotherapy , gene expression , breast cancer , confidence interval , cancer , gene , biology , paleontology , biochemistry

The JBR.10 trial demonstrated benefit from adjuvant cisplatin/vinorelbine (ACT) in early-stage non-small-cell lung cancer (NSCLC). We hypothesized that expression profiling may identify stage-independent subgroups who might benefit from ACT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research